Evaluation of the Agata Sepsis® Platform for Rapid Molecular Diagnosis of Sepsis

Overview

This study assesses the Agata Sepsis® Platform's ability to rapidly identify sepsis-causing bacteria from blood cultures using whole-genome sequencing and deep learning. The platform significantly reduces pathogen identification time compared to conventional biochemical methods, potentially enabling earlier targeted treatment.

Background

Sepsis is a life-threatening systemic inflammatory response caused by infections, leading to high morbidity and mortality worldwide. Early and accurate diagnosis is critical to reduce progression to septic shock and multiorgan failure. Conventional blood culture methods require 48–72 hours for pathogen identification, delaying timely intervention. The Agata Sepsis® Platform offers rapid genomic-based identification, aiming to improve diagnostic speed and accuracy in hospitalized patients.

Data Highlights

The Agata Sepsis® Platform reduces culture positivity time to approximately 4 hours compared to 21–72 hours with conventional methods. It uses whole-genome sequencing and deep learning for simultaneous genus and species identification of sepsis-causing bacteria from blood cultures.

Key Findings

• The Agata Sepsis® Platform identifies bacterial pathogens at genus and species levels using whole-genome sequencing from blood cultures.
• It reduces pathogen identification time from 21–72 hours (conventional methods) to about 4 hours.
• Deep learning algorithms enable accurate detection of genetic markers without requiring bioinformatics expertise for result interpretation.
• The platform includes resistance gene profiling capabilities, with detailed results pending further publication.
• Early identification through this platform could facilitate timely targeted antimicrobial therapy, potentially reducing sepsis-related morbidity and mortality.

Clinical Implications

Implementing the Agata Sepsis® Platform in clinical settings may significantly shorten the time to pathogen identification, allowing earlier initiation of appropriate antimicrobial treatment. This rapid molecular diagnostic tool can improve clinical decision-making, optimize resource use, and potentially reduce sepsis-associated complications and mortality.

Conclusion

The Agata Sepsis® Platform demonstrates promising capabilities for rapid and accurate molecular diagnosis of sepsis pathogens, addressing critical delays inherent in conventional methods. Its adoption could enhance early sepsis management and improve patient outcomes.

References

1. Various Authors/Multiple Years -- Background and Context on Sepsis and Diagnostic Advances